Cargando…

Real-world outcomes of initiating insulin glargine-based treatment versus premixed analog insulins among US patients with type 2 diabetes failing oral antidiabetic drugs

BACKGROUND: In patients with type 2 diabetes mellitus, basal-bolus strategies can improve treatment by offering dosing flexibility, and improved satisfaction, adherence, and clinical outcomes. The purpose of this study was to compare real-world outcomes between US patients initiating analog insulin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baser, Onur, Tangirala, Krishna, Wei, Wenhui, Xie, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794873/ https://www.ncbi.nlm.nih.gov/pubmed/24124384 http://dx.doi.org/10.2147/CEOR.S49279

Ejemplares similares

Real world outcomes of adding rapid-acting insulin versus switching to analog premix insulin among US patients with type 2 diabetes treated with insulin glargine
por: Miao, Raymond, et al.
Publicado: (2013)

Real-world outcomes of US employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn insulin: a comparative retrospective database study
por: Wang, Li, et al.
Publicado: (2013)

Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice*
por: Hammer, H, et al.
Publicado: (2007)

Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland
por: Thomann, Robert, et al.
Publicado: (2020)

Which Patients Will Benefit from a Switch in Therapy from Premixed Insulin to Insulin Glargine plus Oral Antidiabetic Drugs? Further Analysis of the Lantus Registry Study
por: Bu, Shi, et al.
Publicado: (2017)

Pharmacokinetics and pharmacodynamics of insulin glargine–insulin glulisine basal-bolus and twice-daily premixed analog insulin in type 1 diabetes mellitus patients during three standardized meals
por: Lamos, Elizabeth Mary, et al.
Publicado: (2015)

Much Ado About Nothing? A Real-World Study of Patients with Type 2 Diabetes Switching Basal Insulin Analogs
por: Wei, Wenhui, et al.
Publicado: (2014)

Practical Guidance on the Use of Premix Insulin Analogs in Initiating, Intensifying, or Switching Insulin Regimens in Type 2 Diabetes
por: Wu, Ted, et al.
Publicado: (2015)

Insulin glargine overdose
por: Doğan, Fatma Sarı, et al.
Publicado: (2012)

Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Patients with T2D Uncontrolled on NPH or Premixed Insulins as Part of Routine Clinical Practice in Bulgaria: ToUPGRADE Study
por: Kamenov, Zdravko, et al.
Publicado: (2021)

PSUN227 A retrospective comparison of Basal Bolus using Glargine U-300 and Glulisine with Premix Insulin
por: Abraham, Santhosh, et al.
Publicado: (2022)

A Real-World Anti-Diabetes Medication Cost Comparison Between Premixed Insulin Analogs and Long-Acting Insulin Analogs in Chinese Patients with Type 2 Diabetes: A Retrospective Database Analysis
por: Gao, Yue, et al.
Publicado: (2018)

Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus
por: Rys, Przemyslaw, et al.
Publicado: (2015)

A Real-World, Observational Study of the Initiation, Use, and Effectiveness of Basal-Bolus or Premixed Insulin in Japanese People with Type 2 Diabetes
por: Miyoshi, Hideaki, et al.
Publicado: (2021)

Clinical Benefit of Insulin Glargine 300 U/mL Among Patients with Type 2 Diabetes Mellitus Previously Uncontrolled on Basal or Premixed Insulin in Serbia: A Prospective, Observational, Single-Arm, Multicenter, Real-World Study
por: Velojic-Golubovic, Milena, et al.
Publicado: (2021)

Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs
por: Poon, Kitty, et al.
Publicado: (2010)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study
por: Pettus, Jeremy, et al.
Publicado: (2019)

Effects of Twice-Daily Injections of Premixed Insulin Analog on Glycemic Control in Type 2 Diabetic Patients
por: Shimizu, Hiroaki, et al.
Publicado: (2010)

Use of 50/50 Premixed Insulin Analogs in Type 2 Diabetes: Systematic Review and Clinical Recommendations
por: Deed, Gary, et al.
Publicado: (2017)

Efficacy and safety of premixed insulin analogs in Asian patients with type 2 diabetes: A systematic review
por: Sheu, Wayne H‐H, et al.
Publicado: (2017)

Insulin glargine and the risk of cancer
por: Ahmed, FA
Publicado: (2010)

Intensification of Insulin Therapy for Type 2 Diabetic Patients in Primary Care: Basal-Bolus Regimen Versus Premix Insulin Analogs: When and for whom?
por: Mosenzon, Ofri, et al.
Publicado: (2013)

Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin
por: Stürmer, Til, et al.
Publicado: (2013)

Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary care-based analysis
por: Sharplin, Peter, et al.
Publicado: (2009)

Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)
por: Edelman, Steven, et al.
Publicado: (2023)

Insulin Initiation in Insulin-Naïve Korean Type 2 Diabetic Patients Inadequately Controlled on Oral Antidiabetic Drugs in Real-World Practice: The Modality of Insulin Treatment Evaluation Study
por: Kim, Sang Soo, et al.
Publicado: (2015)

Outcomes of transition from premixed and intensive insulin therapies to insulin aspart/degludec co-formulation in type 2 diabetes mellitus: a real-world experience
por: Özçelik, Serhat, et al.
Publicado: (2020)

Effects of basal and premixed insulin on glycemic control in type 2 diabetes patients based on multicenter prospective real‐world data
por: Peng, Ying, et al.
Publicado: (2022)

Glycaemia in low-premixed insulin analogue type 2 diabetes patients in a real-world setting: are the CGM targets met?
por: Krajnc, Mitja, et al.
Publicado: (2023)

A case of hypersensitivity to soluble and isophane insulins but not to insulin glargine
por: Belhekar, Mahesh N., et al.
Publicado: (2015)

Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study
por: Galstyan, Gagik R., et al.
Publicado: (2022)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2021)

Switch to Combined GLP1 Receptor Agonist Lixisenatide with Basal Insulin Glargine in Poorly Controlled T2DM Patients with Premixed Insulin Therapy: A Clinical Observation and Pilot Study in Nine Patients
por: Harreiter, Jürgen, et al.
Publicado: (2017)

Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis
por: Moon, Shinje, et al.
Publicado: (2021)

Protocol to Assess the Biological Activity of Insulin Glargine, Insulin Lispro, and Insulin Aspart In Vitro
por: Garige, Mamatha, et al.
Publicado: (2023)

Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: DosInGlar Study
por: Duque, Natalia, et al.
Publicado: (2021)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real‐world study
por: Sullivan, Sean D., et al.
Publicado: (2019)

Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients
por: Jakobsen, Marie, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_0jslo6kbvusg4et16rp3rikpsh